The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis

Table 2 Base case cost-effectiveness results^a

Strategy	Total		Incremental^b		ICER (£)
Strategy	Cost (£)	QALYs	Cost (£)	QALYs
Current therapy	£7871	17.3431	–	–	–
Old therapy	£12,612	17.2926	£4741	−0.0504	Dominated^c

Current therapy strategy: pegaspargase followed by Erwinia asparaginase in cases of hypersensitivity
Old therapy strategy: native asparaginase followed by Erwinia asparaginase in cases of hypersensitivity
QALY quality-adjusted life years
^aThis table has previously been published in an adapted format [39,40,41]
^bIncremental Cost or Incremental QALYs compared with the current therapy strategy
^cDominated indicates that the current therapy strategy resulted lower costs and more QALY gain versus the old therapy strategy

ISSN: 2191-1991